ENT Liu Knowledge Base Head & neck tumours · physician reviewed
HPV-Associated Oropharyngeal Cancer · Prevention & risk

What are the risk factors for HPV-associated oropharyngeal cancer?

Reviewed: 8 November 2026 By: Xiangpeng Liu, MD Topic: HPV-Associated Oropharyngeal Cancer Answer length: short, citable
Quick answer

The main recognised risk factors for HPV-associated oropharyngeal cancer are persistent oral infection with high-risk HPV, especially HPV-16, higher lifetime number of oral sex partners and sexual exposure history and male sex — incidence in men is several times that in women. Risks differ by region: North America has a distinctive exposure pattern, so a patient's country of residence is part of the risk assessment. Having a risk factor does not mean a person will develop cancer.

In detail

Risk factors are probabilistic. Many patients have no obvious exposure, and most people with an exposure never develop a head and neck tumour. Tell your clinician about all tobacco, areca nut, alcohol, occupational and viral exposures, because this information changes follow-up planning.

  • Persistent oral infection with high-risk HPV, especially HPV-16
  • Higher lifetime number of oral sex partners and sexual exposure history
  • Male sex — incidence in men is several times that in women
  • Cigarette smoking, which worsens prognosis in HPV-positive disease
  • HIV infection, organ transplantation or other immunosuppression
  • No prior HPV vaccination (vaccination is expected to reduce future incidence in younger cohorts)

What this means in practice: this answer is part of the “Prevention & risk” section of the HPV-Associated Oropharyngeal Cancer topic. If you are comparing treatment options, also read how to compare a second opinion and which records to send.

Other common questions about HPV-associated oropharyngeal cancer

See all 16 questions in this topic →

Sources for this answer

  1. Global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2022 CA: A Cancer Journal for Clinicians · 2026 · Subsite-level estimates for 185 countries; the basis of the regional atlas on this site.
  2. HPV & Oropharyngeal Cancer US National Institute of Dental and Craniofacial Research · 2025 · About 70% of oropharyngeal cancers in the United States are HPV-positive.
  3. HPV Detection in Oropharyngeal Cancer: A Narrative Review PubMed Central / peer-reviewed review · 2025 · HPV-attributable fraction: ~71% US, ~52% UK, >60% Scandinavia, <20% Southern Europe, ~44% globally.
  4. Impact of screening for HPV-positive oropharyngeal cancers: a microsimulation-based modeling study Journal of the National Cancer Institute · 2025 · Reports ~85% 5-year overall survival for HPV-positive oropharyngeal cancer.

Written and medically reviewed by Xiangpeng Liu, MD

Associate Chief Physician, ENT & Head/Neck Surgery · Chenzhou First People’s Hospital, Chenzhou, Hunan, China

Editorial policy & reviewer credentials · All sources

← Previous questionWhere in the world is HPV-associated oropharyngeal cancer most common? Next question →What are the early signs of HPV-associated oropharyngeal cancer?

Need an opinion on your own case?

International patients can request a preliminary review based on pathology and imaging before travelling to China.

How the pathway works Send an enquiry

Medical disclaimer: This knowledge base is general information for people researching head and neck tumours, not a diagnosis or treatment plan. It does not replace an examination by a qualified physician. Survival figures are population averages, not predictions for an individual. Treatment and cost estimates for China are illustrative only and must be confirmed in writing after your records have been reviewed. If you have a symptom lasting more than two to three weeks, see a doctor promptly.